HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes.

Neil J. Shah,David H Aggen,Junting Zheng,Andrew Niederhausern,Syed Muneeb Alam,Om Balar,Nadia Bahadur,Adam Watson,Ashley M. Regazzi,Neha Ratna,Samuel A Funt,Min Yuen Teo,Eugene J. Pietzak,David B. Solit,Dean F. Bajorin,John Philip,Jonathan E. Rosenberg,Irina Ostrovnaya,Hikmat A. Al-Ahmadie,Gopa Iyer
DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.574
IF: 45.3
2024-01-31
Journal of Clinical Oncology
Abstract:574 Background: Novel HER2-directed targeted therapies have revolutionized the treatment paradigm for patients with breast cancer and are being actively investigated in BC. The impact of pathogenic HER2 mutation and/or its amplification on clinical outcomes across various stages of BC is underdefined. Methods: In our retrospective study, we identified 999 BC patients who underwent genetic profiling using MSKCC IMPACT and had at least one year of follow-up. The BC disease states included non-muscle invasive (NMIBC), muscle-invasive (MIBC), and metastatic (MetBC). Patient demographics and HER2 alteration (mutation or amplification) were analyzed and compared closest to the time of IMPACT sampling, using the Kruskal-Wallis rank sum test or the Fisher’s exact test. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS) for MIBC and MetBC, and advanced disease-free survival (ADFS) for NMIBC. The log-rank test and Cox proportional hazard regression were used in survival analyses. Results: The study cohort included NMIBC:359, MIBC:429, and MetBC:211 patients at the time of profiling and the overall incidence of HER2 alteration (mutation or amplification) was 13% (48), 17% (75), and 19% (41), respectively. HER2 Amplification was significantly lower for NMIBC (2.8%) compared to MIBC (9.3%) and MetBC (10%), p<0.001. HER2 S310F and S310Y were the most common pathogenic mutations. Age, race, gender, and smoking status were not associated with the incidence of HER2 alteration for any BC disease states. The median follow-up for NMIBC, MIBC, and MetBC was 5.3, 3.6, and 6.5 years, respectively. HER2 status did not influence ADFS for NMIBC; PFS and OS for MIBC regardless of neoadjuvant cisplatin chemotherapy (chemo); OS for 1st line (1L) MetBC treated with gemcitabine plus platinum (GC) chemo or 2nd line (2L) immune checkpoint inhibitor (ICI) therapy post 1L-chemo (table). Conclusions: We present one of the largest and comprehensive study of HER2 mutation in BC. Overall, HER2 amplification was significantly less frequent for NMIBC. HER2 alterations were not a prognostic marker for NMIBC or MIBC independent of neoadjuvant cisplatin-based chemo, MetBC- 1L GC-chemo and 2L ICI post GC-chemo. Further studies examining IHC and functional HER2 PET imaging are needed to further define the HER2 BC landscape. [Table: see text]
oncology
What problem does this paper attempt to address?